File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Ovarian clear cell carcinoma with choriocarcinomatous differentiation: Report of a rare and aggressive tumor
  • Basic View
  • Metadata View
  • XML View
TitleOvarian clear cell carcinoma with choriocarcinomatous differentiation: Report of a rare and aggressive tumor
 
AuthorsHu, YJ
Ip, PPC1
Chan, KKL1
Tam, KF1
Ngan, HYS1
 
Keywordschoriocarcinoma
clear cell carcinoma
neoadjuvant chemotherapy
nongestatational choriocarcinoma
ovarian carcinoma
 
Issue Date2010
 
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.intjgynpathology.com
 
CitationInternational Journal Of Gynecological Pathology, 2010, v. 29 n. 6, p. 539-545 [How to Cite?]
DOI: http://dx.doi.org/10.1097/PGP.0b013e3181e7cc66
 
AbstractOvarian epithelial tumors of nongerm cell origin with true choriocarcinomatous differentiation are rare. To date, there are only 5 documented cases in the literature. In the reported cases, the epithelial component was of mixed cell types or of mucinous differentiation. To the best of our knowledge, an ovarian carcinoma exclusively of clear cell differentiation coexisting with a pure choriocarcinoma has not been reported earlier. A 48-year-old postmenopausal woman was found to have a large pelvic mass with lung and liver metastases. Trucut biopsy of the mass showed a poorly differentiated carcinoma that was immunoreactive for CK7 and hCG. She received 6 cycles of neoadjuvant chemotherapy that included 3 cycles of etoposide/cisplatin and 3 cycles of paclitaxel/etoposide-paclitaxel/carboplatin (TE/TP) with partial response. Debulking surgery was carried out subsequently. Pathologic examination showed an ovarian clear cell carcinoma with a second component of choriocarcinoma in which the bilaminar growth pattern of cytotrophoblast and syncytiotrophoblasts was striking. Despite additional therapy, which included 2 cycles of TE/TP and 2 cycles of gemcitabine/taxotere, the disease progressed and the patient died 11 months postoperatively. This report showed that ovarian clear cell carcinoma with choriocarcinomatous differentiation is a highly aggressive tumor and has a very poor prognosis. Nonetheless, there may be a role for neoadjuvant chemotherapy that targets both the clear cell and the choriocarcinoma components to reduce the volume of the disease before debulking surgery. © 2010 International Society of Gynecological Pathologists.
 
ISSN0277-1691
2012 Impact Factor: 1.413
2012 SCImago Journal Rankings: 0.569
 
DOIhttp://dx.doi.org/10.1097/PGP.0b013e3181e7cc66
 
ISI Accession Number IDWOS:000283264400006
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorHu, YJ
 
dc.contributor.authorIp, PPC
 
dc.contributor.authorChan, KKL
 
dc.contributor.authorTam, KF
 
dc.contributor.authorNgan, HYS
 
dc.date.accessioned2011-07-27T01:39:12Z
 
dc.date.available2011-07-27T01:39:12Z
 
dc.date.issued2010
 
dc.description.abstractOvarian epithelial tumors of nongerm cell origin with true choriocarcinomatous differentiation are rare. To date, there are only 5 documented cases in the literature. In the reported cases, the epithelial component was of mixed cell types or of mucinous differentiation. To the best of our knowledge, an ovarian carcinoma exclusively of clear cell differentiation coexisting with a pure choriocarcinoma has not been reported earlier. A 48-year-old postmenopausal woman was found to have a large pelvic mass with lung and liver metastases. Trucut biopsy of the mass showed a poorly differentiated carcinoma that was immunoreactive for CK7 and hCG. She received 6 cycles of neoadjuvant chemotherapy that included 3 cycles of etoposide/cisplatin and 3 cycles of paclitaxel/etoposide-paclitaxel/carboplatin (TE/TP) with partial response. Debulking surgery was carried out subsequently. Pathologic examination showed an ovarian clear cell carcinoma with a second component of choriocarcinoma in which the bilaminar growth pattern of cytotrophoblast and syncytiotrophoblasts was striking. Despite additional therapy, which included 2 cycles of TE/TP and 2 cycles of gemcitabine/taxotere, the disease progressed and the patient died 11 months postoperatively. This report showed that ovarian clear cell carcinoma with choriocarcinomatous differentiation is a highly aggressive tumor and has a very poor prognosis. Nonetheless, there may be a role for neoadjuvant chemotherapy that targets both the clear cell and the choriocarcinoma components to reduce the volume of the disease before debulking surgery. © 2010 International Society of Gynecological Pathologists.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationInternational Journal Of Gynecological Pathology, 2010, v. 29 n. 6, p. 539-545 [How to Cite?]
DOI: http://dx.doi.org/10.1097/PGP.0b013e3181e7cc66
 
dc.identifier.doihttp://dx.doi.org/10.1097/PGP.0b013e3181e7cc66
 
dc.identifier.epage545
 
dc.identifier.hkuros186767
 
dc.identifier.hkuros188236
 
dc.identifier.isiWOS:000283264400006
 
dc.identifier.issn0277-1691
2012 Impact Factor: 1.413
2012 SCImago Journal Rankings: 0.569
 
dc.identifier.issue6
 
dc.identifier.pmid20881859
 
dc.identifier.scopuseid_2-s2.0-78149285342
 
dc.identifier.spage539
 
dc.identifier.urihttp://hdl.handle.net/10722/135675
 
dc.identifier.volume29
 
dc.languageeng
 
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.intjgynpathology.com
 
dc.publisher.placeUnited States
 
dc.relation.ispartofInternational Journal of Gynecological Pathology
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdenocarcinoma, Clear Cell - pathology - therapy
 
dc.subject.meshAntineoplastic Agents - therapeutic use
 
dc.subject.meshChoriocarcinoma, Non-gestational - pathology - therapy
 
dc.subject.meshGynecologic Surgical Procedures
 
dc.subject.meshOvarian Neoplasms - pathology - therapy
 
dc.subjectchoriocarcinoma
 
dc.subjectclear cell carcinoma
 
dc.subjectneoadjuvant chemotherapy
 
dc.subjectnongestatational choriocarcinoma
 
dc.subjectovarian carcinoma
 
dc.titleOvarian clear cell carcinoma with choriocarcinomatous differentiation: Report of a rare and aggressive tumor
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Hu, YJ</contributor.author>
<contributor.author>Ip, PPC</contributor.author>
<contributor.author>Chan, KKL</contributor.author>
<contributor.author>Tam, KF</contributor.author>
<contributor.author>Ngan, HYS</contributor.author>
<date.accessioned>2011-07-27T01:39:12Z</date.accessioned>
<date.available>2011-07-27T01:39:12Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>International Journal Of Gynecological Pathology, 2010, v. 29 n. 6, p. 539-545</identifier.citation>
<identifier.issn>0277-1691</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/135675</identifier.uri>
<description.abstract>Ovarian epithelial tumors of nongerm cell origin with true choriocarcinomatous differentiation are rare. To date, there are only 5 documented cases in the literature. In the reported cases, the epithelial component was of mixed cell types or of mucinous differentiation. To the best of our knowledge, an ovarian carcinoma exclusively of clear cell differentiation coexisting with a pure choriocarcinoma has not been reported earlier. A 48-year-old postmenopausal woman was found to have a large pelvic mass with lung and liver metastases. Trucut biopsy of the mass showed a poorly differentiated carcinoma that was immunoreactive for CK7 and hCG. She received 6 cycles of neoadjuvant chemotherapy that included 3 cycles of etoposide/cisplatin and 3 cycles of paclitaxel/etoposide-paclitaxel/carboplatin (TE/TP) with partial response. Debulking surgery was carried out subsequently. Pathologic examination showed an ovarian clear cell carcinoma with a second component of choriocarcinoma in which the bilaminar growth pattern of cytotrophoblast and syncytiotrophoblasts was striking. Despite additional therapy, which included 2 cycles of TE/TP and 2 cycles of gemcitabine/taxotere, the disease progressed and the patient died 11 months postoperatively. This report showed that ovarian clear cell carcinoma with choriocarcinomatous differentiation is a highly aggressive tumor and has a very poor prognosis. Nonetheless, there may be a role for neoadjuvant chemotherapy that targets both the clear cell and the choriocarcinoma components to reduce the volume of the disease before debulking surgery. &#169; 2010 International Society of Gynecological Pathologists.</description.abstract>
<language>eng</language>
<publisher>Lippincott Williams &amp; Wilkins. The Journal&apos;s web site is located at http://www.intjgynpathology.com</publisher>
<relation.ispartof>International Journal of Gynecological Pathology</relation.ispartof>
<subject>choriocarcinoma</subject>
<subject>clear cell carcinoma</subject>
<subject>neoadjuvant chemotherapy</subject>
<subject>nongestatational choriocarcinoma</subject>
<subject>ovarian carcinoma</subject>
<subject.mesh>Adenocarcinoma, Clear Cell - pathology - therapy</subject.mesh>
<subject.mesh>Antineoplastic Agents - therapeutic use</subject.mesh>
<subject.mesh>Choriocarcinoma, Non-gestational - pathology - therapy</subject.mesh>
<subject.mesh>Gynecologic Surgical Procedures</subject.mesh>
<subject.mesh>Ovarian Neoplasms - pathology - therapy</subject.mesh>
<title>Ovarian clear cell carcinoma with choriocarcinomatous differentiation: Report of a rare and aggressive tumor</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1097/PGP.0b013e3181e7cc66</identifier.doi>
<identifier.pmid>20881859</identifier.pmid>
<identifier.scopus>eid_2-s2.0-78149285342</identifier.scopus>
<identifier.hkuros>186767</identifier.hkuros>
<identifier.hkuros>188236</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-78149285342&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>29</identifier.volume>
<identifier.issue>6</identifier.issue>
<identifier.spage>539</identifier.spage>
<identifier.epage>545</identifier.epage>
<identifier.isi>WOS:000283264400006</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong